89bio KOL Webinar on Severe Hypertriglyceridemia (SHTG)
| DATE: | May 4, 2022 |
|---|---|
| TIME: | 2:00 PM EDT |
| LOCATION: | N/A |
About The Event
The webinar will feature presentations from Key Opinion Leaders (KOLs) Harold Bays, MD (President, Louisville Metabolic and Atherosclerosis Research Center, Inc.), and Deepak L. Bhatt, MD, MPH (Brigham and Women’s Health and Harvard Medical School).
- Dr. Bays will discuss the current disease state, treatment landscape, and unmet medical need for patients with severe hypertriglyceridemia (SHTG).
- Dr. Bhatt will then discuss 89bio’s ENTRIGUE Phase 2 clinical trial of pegozafermin in SHTG patients, prior data, the therapeutic rationale for developing pegozafermin in this setting, its unique mechanism of action and the potential to offer a compelling treatment option.
- Following Dr. Bays’ and Dr. Bhatt’s presentations, the 89bio leadership team will discuss the clinical/regulatory development path, and potential market opportunity for pegozafermin in SHTG.
A live question and answer session will follow the formal presentation.